# Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

> **NCT05871970** · PHASE2 · RECRUITING · sponsor: **Protara Therapeutics** · enrollment: 38 (estimated)

## Conditions studied

- Lymphatic Malformation

## Interventions

- **BIOLOGICAL:** TARA-002

## Key facts

- **NCT ID:** NCT05871970
- **Lead sponsor:** Protara Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-18
- **Primary completion:** 2026-12
- **Final completion:** 2027-05
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05871970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05871970, "Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05871970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*